{
  "source": "PA-Med-Nec-Firdapse.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 2177-7\nProgram Prior Authorization/Medical Necessity\nMedication Firdapse® (amifampridine)\nP&T Approval Date 11/2019, 11/2020, 11/2021, 3/2022, 11/2022, 11/2023, 11/2024\nEffective Date 2/1/2025\n1. Background:\nFirdapse (amifampridine) is a potassium channel blocker indicated for the treatment of Lambert-\nEaton myasthenic syndrome (LEMS) in adults and pediatric patients 6 years of age and older.1\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Firdapse will be approved based on all of the following criteria:\na. Diagnosis of Lambert-Eaton myasthenic syndrome (LEMS)\n-AND-\nb. Prescribed by or in consultation with a specialist in the treatment of LEMS (e.g.,\nneurologist or oncologist)\n-AND-\nc. Patient is not receiving Firdapse in combination with similar potassium channel\nblockers [e.g., Ampyra (dalfampridine)]\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Firdapse will be approved based on both the following criteria:\na. Documentation of positive clinical response to Firdapse therapy\n-AND-\nb. Patient is not receiving Firdapse in combination with similar potassium channel\nblockers [e.g., Ampyra (dalfampridine)]\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\n© 2024 UnitedHealthcare Services, Inc.\n1\nmanagement programs may apply.\n3. Additional Clinical Programs:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Firdapse [package insert]. Coral Gables, FL: Catalyst Pharmaceuticals, Inc.; May 2024.\nProgram Prior Authorization/M",
    "rogram\nand/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Firdapse [package insert]. Coral Gables, FL: Catalyst Pharmaceuticals, Inc.; May 2024.\nProgram Prior Authorization/Medical Necessity - Firdapse (amifampridine)\nChange Control\n11/2019 New program\n11/2020 Annual review with no changes to coverage criteria. Updated\nreferences.\n11/2021 Annual review with no changes to coverage criteria. Updated\nreferences.\n3/2022 Removed step through Ruzurgi due to FDAs conversion of Ruzurgi\nfrom full approval to tentative approval.\n11/2022 Updated background to reflect new pediatric indication for patients 6\nyears of age and older.\n11/2023 Added “Diagnosis of” to initial criteria with no change to clinical intent.\n11/2024 Annual review with no changes to coverage criteria. Updated reference.\n© 2024 UnitedHealthcare Services, Inc.\n2"
  ]
}